Compare Danaher Corporation (DHR) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs M&T Bank Corporation — how do they compare? Danaher Corporation trades at $207.4 (market cap $147.18B), while M&T Bank Corporation trades at $251.93 (market cap $36.27B). The key difference: Danaher Corporation is far larger — about 4.1× M&T Bank Corporation's market cap, and M&T Bank Corporation pays the higher dividend (2.39%). Which is the better fit depends on your goals.
| DHR | MTB | |
|---|---|---|
Market Cap | $147.18B | $36.27B |
Sector | Health | Financials |
52-Week High | $242.05 | $254.04 |
52-Week Low | $161.91 | $178.63 |
Enterprise Value | $169.39B | — |
Dividend Yield | 0.76% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
M&T Bank Corporation (MTB) trades at $250.45, up 0.12% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock is supported by strong fundamentals, including a net income margin of 30.85% and a P/E ratio of 13.26, indicating reasonable valuation. Recent Q2 2026 results showed record EPS of $5.35, exceeding expectations, driven by loan growth and net interest income. The consensus price target is $255.92, suggesting modest upside from current levels.
The outlook for MTB remains positive, supported by operational excellence and dividend payments, but risks include macroeconomic sensitivity and competitive pressures in regional banking. Investor sentiment is cautiously optimistic, with analysts largely holding a neutral to buy stance, while institutional ownership trends and cash flow management will be key to sustaining growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
